ALXN1840 shows greater neurologic benefit in Phase 3 FoCus analyses

New analyses from the randomized Phase 3 FoCus trial reported that ALXN1840 produced greater neurologic improvement and significantly less worsening than standard of care through Week 48, with durable benefit reported over multiple years; the data are being presented at the AAN Annual Meeting 2026.

Monopar Therapeutics announced new analyses from the randomized, controlled Phase 3 FoCus trial of ALXN1840. The findings are being presented at the American Academy of Neurology Annual Meeting 2026, held April 18–22. The presentation is a late-breaker oral and poster by Dr. Peter Hedera of the University of Louisville School of Medicine. The reported analyses focus on neurologic outcomes in Wilson disease patients who had neurologic symptoms at baseline. Key findings: - The randomized Phase 3 FoCus trial compared ALXN1840 with standard of care in Wilson disease patients with neurologic symptoms at baseline. - The article reports that ALXN1840 provided greater neurologic improvement and significantly less worsening compared with standard of care through Week 48. - Durable neurologic benefit was reported over multiple years of treatment. - The data are being presented in a late-breaker oral and poster session by Dr. Peter Hedera at AAN 2026. - The article mentions Monopar Therapeutics announced these analyses. Summary: The reported analyses indicate greater neurologic benefit and less clinical worsening with ALXN1840 through Week 48, and investigators reported durable effects over multiple years. The results are being presented at the AAN Annual Meeting; further steps or regulatory outcomes are undetermined at this time.